Eli Lilly and Stock Price, News & Analysis (NYSE:LLY)

$86.45 0.58 (0.68 %)
(As of 12/11/2017 02:43 AM ET)
Previous Close$85.87
Today's Range$85.47 - $86.46
52-Week Range$67.22 - $89.09
Volume3.78 million shs
Average Volume3.67 million shs
Market Capitalization$95.19 billion
P/E Ratio21.14
Dividend Yield2.42%
Beta0.35

About Eli Lilly and (NYSE:LLY)

Eli Lilly and logoEli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company's human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment operates through the Company's Elanco division, which develops, manufactures and markets products for both food animals and companion animals. The Company's human pharmaceutical products include endocrinology products, neuroscience products, oncology products, immunology products and cardiovascular products. The Company's animal health products segment includes products for food animals and products for companion animals. As of December 31, 2016, the Company manufactured and distributed its products through facilities in the United States, Puerto Rico and 14 other countries.

Receive LLY News and Ratings via Email

Sign-up to receive the latest news and ratings for LLY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceuticals
Sub-IndustryPharmaceuticals
SectorHealthcare
SymbolNYSE:LLY
CUSIP53245710
Phone+1-317-2762000

Debt

Debt-to-Equity Ratio0.66%
Current Ratio1.38%
Quick Ratio1.03%

Price-To-Earnings

Trailing P/E Ratio21.14
Forward P/E Ratio20.53
P/E Growth1.9

Sales & Book Value

Annual Sales$21.22 billion
Price / Sales4.49
Cash Flow$4.74 per share
Price / Cash18.24
Book Value$12.76 per share
Price / Book6.78

Profitability

Trailing EPS$2.10
Net Income$2.74 billion
Net Margins9.90%
Return on Equity30.27%
Return on Assets10.82%

Miscellaneous

Employees41,975
Outstanding Shares1,101,090,000

Eli Lilly and (NYSE:LLY) Frequently Asked Questions

What is Eli Lilly and's stock symbol?

Eli Lilly and trades on the New York Stock Exchange (NYSE) under the ticker symbol "LLY."

How often does Eli Lilly and pay dividends? What is the dividend yield for Eli Lilly and?

Eli Lilly and announced a quarterly dividend on Monday, October 16th. Shareholders of record on Wednesday, November 15th will be paid a dividend of $0.52 per share on Friday, December 8th. This represents a $2.08 annualized dividend and a yield of 2.41%. The ex-dividend date of this dividend is Tuesday, November 14th. View Eli Lilly and's Dividend History.

How were Eli Lilly and's earnings last quarter?

Eli Lilly and Company (NYSE:LLY) released its quarterly earnings results on Tuesday, October, 24th. The company reported $1.05 earnings per share for the quarter, topping the consensus estimate of $1.03 by $0.02. The company had revenue of $5.66 billion for the quarter, compared to analyst estimates of $5.52 billion. Eli Lilly and had a net margin of 9.90% and a return on equity of 30.27%. The business's revenue was up 9.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.88 earnings per share. View Eli Lilly and's Earnings History.

When will Eli Lilly and make its next earnings announcement?

Eli Lilly and is scheduled to release their next quarterly earnings announcement on Wednesday, January, 31st 2018. View Earnings Estimates for Eli Lilly and.

What guidance has Eli Lilly and issued on next quarter's earnings?

Eli Lilly and issued an update on its FY17 earnings guidance on Tuesday, October, 24th. The company provided earnings per share (EPS) guidance of $4.15-4.25 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $4.16. The company issued revenue guidance of $22.4-22.7 billion, compared to the consensus revenue estimate of $22.51 billion.

Where is Eli Lilly and's stock going? Where will Eli Lilly and's stock price be in 2017?

15 Wall Street analysts have issued twelve-month price targets for Eli Lilly and's stock. Their predictions range from $73.00 to $105.00. On average, they anticipate Eli Lilly and's share price to reach $91.60 in the next twelve months. View Analyst Ratings for Eli Lilly and.

What are Wall Street analysts saying about Eli Lilly and stock?

Here are some recent quotes from research analysts about Eli Lilly and stock:

  • 1. According to Zacks Investment Research, "Lilly’s third-quarter 2017 results were strong with the company beating estimates on both counts. Lilly also raised its sales and earnings outlook for the second time this year mainly backed by strong uptake trends of new products. Lilly is also exploring strategic alternatives for the Animal Health business, a prudent decision in our view. Lilly’s new products like Trulicity, Taltz, Basaglar, Cyramza, Jardiance and Lartruvo have been driving revenues and the trend is expected to continue. Lilly expects to launch 20 new products between 2014 and 2023, including at least two new indications/line extensions on an average every year. However, key drug Alimta will continue to be impacted by competition. Meanwhile, the recent high-profile pipeline setbacks, competition from immuno-oncology agents, loss of exclusivity for many drugs, and weak performance of the Animal Health segment this year are an investor concern." (10/30/2017)
  • 2. Jefferies Group LLC analysts commented, "Date and time of first dissemination: July 17, 2017, 08:17 ET Date and time of production: July 17, 2017, 08:17 ET Target Price / Valuation Methodology: Mallinckrodt plc – MNK Our discounted cash flow (DCF) analysis leads us to a price target of $87/share for MNK shares. Our DCF considers our estimates through 2027, slowing growth through 2033 and a 10% terminal decline thereafter. In addition, we expect Mallinckrodt’s margin structure to remain somewhat consistent with our 2027 estimates. We estimate a weighted average cost of capital (WACC) of 11.4% which is in line with other companies in Mallinckrodt’s peer set due to the company’s manageable leverage and consistent cash generation potential." (7/13/2017)
  • 3. UBS AG analysts commented, "We adjust our model to account for two months of reported IMS Rx data. Key growth drivers such as Trulicity and Taltz have performed better than expected while Basaglar (insulin glargine) was modestly lower than anticipated. Our overall 2017 revenues are largely unchanged as better than expected sales (largely from the Taltz and Trulicity) offset softer than expected sales of other products, and our 2017 EPS of $4.15 remain unchanged. For 2018, our revenues went up ~$70M largely driven by Taltz and we raise our EPS to $4.45 from $4.40." (3/20/2017)

Who are some of Eli Lilly and's key competitors?

Who are Eli Lilly and's key executives?

Eli Lilly and's management team includes the folowing people:

  • David A. Ricks, Chairman of the Board, President, Chief Executive Officer (Age 49)
  • Derica W. Rice, Chief Financial Officer, Executive Vice President - Global Services (Age 52)
  • Jan M. Lundberg Ph.D., Executive Vice President - Science and Technology, President - Lilly Research Laboratories (Age 63)
  • Melissa Stapleton Barnes, Senior Vice President - Enterprise Risk Management and Chief Ethics and Compliance Officer (Age 48)
  • Michael J. Harrington, Senior Vice President, General Counsel (Age 54)
  • Stephen F. Fry, Senior Vice President - Human Resources and Diversity (Age 51)
  • Enrique A. Conterno, Senior Vice President and President - Lilly Diabetes and President - Lilly USA (Age 50)
  • Susan Mahony Ph.D., Senior Vice President and President - Lilly Oncology (Age 52)
  • Barton R. Peterson, Senior Vice President - Corporate Affairs and Communications (Age 58)
  • Leigh Ann Pusey, Senior Vice President - Corporate Affairs and Communications

Who owns Eli Lilly and stock?

Eli Lilly and's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Bank of New York Mellon Corp (1.03%), Janus Henderson Group PLC (0.99%), Legal & General Group Plc (0.47%), Swiss National Bank (377,575.22%), Capital International Investors (0.37%) and Schwab Charles Investment Management Inc. (0.37%). Company insiders that own Eli Lilly and stock include Alfonso G Zulueta, David A Ricks, Derica W Rice, Donald A Zakrowski, Enrique A Conterno, Jackson P Tai, Lilly Endowment Inc, Maria A Crowe, Melissa S Barnes, Michael J Harrington, R David Hoover, Stephen F Fry and Susan Mahony. View Institutional Ownership Trends for Eli Lilly and.

Who sold Eli Lilly and stock? Who is selling Eli Lilly and stock?

Eli Lilly and's stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Point72 Asset Management L.P., State of Tennessee Treasury Department, Capital Bank & Trust Co, Teacher Retirement System of Texas, Rothschild Asset Management Inc., Forsta AP Fonden and California State Teachers Retirement System. Company insiders that have sold Eli Lilly and company stock in the last year include Alfonso G Zulueta, Derica W Rice, Donald A Zakrowski, Enrique A Conterno, Lilly Endowment Inc, Melissa S Barnes, Michael J Harrington and Susan Mahony. View Insider Buying and Selling for Eli Lilly and.

Who bought Eli Lilly and stock? Who is buying Eli Lilly and stock?

Eli Lilly and's stock was bought by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Schwab Charles Investment Management Inc., Skandinaviska Enskilda Banken AB publ, American Century Companies Inc., Candriam Luxembourg S.C.A., Schroder Investment Management Group, Sector Gamma AS and Honeywell International Inc.. Company insiders that have bought Eli Lilly and stock in the last two years include Jackson P Tai and R David Hoover. View Insider Buying and Selling for Eli Lilly and.

How do I buy Eli Lilly and stock?

Shares of Eli Lilly and can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Eli Lilly and's stock price today?

One share of Eli Lilly and stock can currently be purchased for approximately $86.45.

How big of a company is Eli Lilly and?

Eli Lilly and has a market capitalization of $95.19 billion and generates $21.22 billion in revenue each year. The company earns $2.74 billion in net income (profit) each year or $2.10 on an earnings per share basis. Eli Lilly and employs 41,975 workers across the globe.

How can I contact Eli Lilly and?

Eli Lilly and's mailing address is Lilly Corporate Ctr, Drop Code 1112, INDIANAPOLIS, IN 46285, United States. The company can be reached via phone at +1-317-2762000 or via email at [email protected]


MarketBeat Community Rating for Eli Lilly and (LLY)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  727 (Vote Outperform)
Underperform Votes:  549 (Vote Underperform)
Total Votes:  1,276
MarketBeat's community ratings are surveys of what our community members think about Eli Lilly and and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Eli Lilly and (NYSE:LLY) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.532.532.582.68
Ratings Breakdown: 1 Sell Rating(s)
7 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
7 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
6 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
4 Hold Rating(s)
14 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $90.41$90.18$88.94$91.12
Price Target Upside: 5.65% upside10.05% upside7.64% upside14.83% upside

Eli Lilly and (NYSE:LLY) Consensus Price Target History

Price Target History for Eli Lilly and (NYSE:LLY)

Eli Lilly and (NYSE:LLY) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/5/2017BMO Capital MarketsSet Price TargetSell$73.00LowView Rating Details
11/21/2017Morgan StanleyBoost Price TargetEqual Weight -> Equal Weight$86.00 -> $90.00N/AView Rating Details
10/26/2017Berenberg BankReiterated RatingBuy$98.00N/AView Rating Details
10/23/2017Leerink SwannBoost Price TargetMarket Perform$92.00 -> $93.00N/AView Rating Details
10/13/2017Piper Jaffray CompaniesReiterated RatingBuy$105.00N/AView Rating Details
10/13/2017BarclaysBoost Price TargetOverweight$90.00 -> $98.00N/AView Rating Details
10/10/2017Credit Suisse GroupDowngradeOutperform -> Neutral$84.23 -> $88.00N/AView Rating Details
10/5/2017Goldman Sachs GroupReiterated RatingBuy$92.00 -> $95.00N/AView Rating Details
10/4/2017CowenReiterated RatingBuy$95.00LowView Rating Details
9/11/2017Jefferies GroupReiterated RatingBuy$89.00 -> $89.00LowView Rating Details
7/26/2017OppenheimerDowngradeOutperform -> Market Perform$90.00 -> $90.00LowView Rating Details
7/17/2017Deutsche BankReiterated RatingBuy$90.00 -> $91.00LowView Rating Details
7/4/2017CitigroupReiterated RatingBuy$100.00LowView Rating Details
5/21/2017Sanford C. BernsteinReiterated RatingOutperform$88.00MediumView Rating Details
4/27/2017ArgusDowngradeBuy -> Hold$64.18 -> $81.00LowView Rating Details
11/26/2016J P Morgan Chase & CoReiterated RatingOverweightN/AView Rating Details
11/25/2016Atlantic SecuritiesDowngradeOverweight -> NeutralN/AView Rating Details
10/27/2016Societe GeneraleReiterated RatingHold$78.00N/AView Rating Details
6/15/2016SunTrust BanksReiterated RatingBuyN/AView Rating Details
12/22/2015Bank of AmericaReiterated RatingBuy$104.00 -> $108.00N/AView Rating Details
(Data available from 12/11/2015 forward)

Earnings

Eli Lilly and (NYSE:LLY) Earnings History and Estimates Chart

Earnings by Quarter for Eli Lilly and (NYSE:LLY)

Eli Lilly and (NYSE LLY) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
1/31/2018$1.07N/AView Earnings Details
10/24/2017Q3 2017$1.03$1.05$5.52 billion$5.66 billionViewN/AView Earnings Details
7/25/2017Q2 2017$1.05$1.11$5.60 billion$5.82 billionViewN/AView Earnings Details
4/25/2017Q1 17$0.96$0.98$5.22 billion$5.23 billionViewN/AView Earnings Details
1/31/2017Q416$0.98$0.95$5.54 billion$5.76 billionViewN/AView Earnings Details
10/25/2016Q316$0.96$0.88$4.23 billion$5.19 billionViewListenView Earnings Details
7/26/2016Q216$0.86$0.86$5.14 billion$5.40 billionViewListenView Earnings Details
4/26/2016Q116$0.85$0.83$4.82 billion$4.87 billionViewListenView Earnings Details
1/28/2016Q415$0.78$0.78$5.33 billion$5.38 billionViewListenView Earnings Details
10/22/2015Q315$0.76$0.89$4.99 billion$4.96 billionViewListenView Earnings Details
7/23/2015Q215$0.74$0.90$4.89 billion$4.98 billionViewListenView Earnings Details
4/23/2015Q115$0.76$0.87$4.62 billion$4.64 billionViewN/AView Earnings Details
1/30/2015Q414$0.74$0.75$5.21 billion$5.12 billionViewN/AView Earnings Details
10/23/2014Q314$0.66$0.66$4.83 billion$4.88 billionViewListenView Earnings Details
7/24/2014Q214$0.66$0.68$4.88 billion$4.94 billionViewN/AView Earnings Details
4/24/2014Q114$0.70$0.70$4.78 billion$4.68 billionViewN/AView Earnings Details
1/30/2014Q413$0.72$0.74$5.46 billion$5.81 billionViewListenView Earnings Details
10/23/2013Q313$1.04$1.11$5.76 billion$5.77 billionViewN/AView Earnings Details
7/24/2013Q2 2013$1.01$1.16$5.82 billion$5.93 billionViewN/AView Earnings Details
4/24/2013Q1 2013$1.05$1.14$5.66 billion$5.60 billionViewN/AView Earnings Details
1/29/2013Q4 2012$0.82$0.85$5.78 billion$5.96 billionViewN/AView Earnings Details
10/24/2012$0.82$0.79ViewN/AView Earnings Details
7/25/2012$0.76$0.83ViewN/AView Earnings Details
4/25/2012$0.80$0.92ViewN/AView Earnings Details
1/31/2012$0.80$0.87ViewN/AView Earnings Details
10/20/2011$1.12$1.13ViewN/AView Earnings Details
7/21/2011$1.18$1.18ViewN/AView Earnings Details
4/18/2011$1.16$1.24ViewN/AView Earnings Details
1/27/2011$1.10$1.11ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Eli Lilly and (NYSE:LLY) Earnings Estimates

2017 EPS Consensus Estimate: $4.12
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172$0.98$0.98$0.98
Q2 20172$1.04$1.06$1.05
Q3 20173$1.01$1.06$1.04
Q4 20172$1.03$1.07$1.05
(Data provided by Zacks Investment Research)

Dividends

Eli Lilly and (NYSE:LLY) Dividend Information

Most Recent Dividend:12/8/2017
Annual Dividend:$2.08
Dividend Yield:2.41%
Dividend Growth:1.30% (3 Year Average)
Payout Ratio:99.05% (Trailing 12 Months of Earnings)
49.41% (Based on This Year's Estimates)
44.73% (Based on Next Year's Estimates)
Track Record:2 Years of Consecutive Dividend Growth
Frequency:Quarterly Dividend
Dividend Payments by Quarter for Eli Lilly and (NYSE:LLY)

Eli Lilly and (NYSE:LLY) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
10/16/2017quarterly$0.522.42%11/14/201711/15/201712/8/2017
6/19/2017quarterly$0.522.51%8/11/20178/15/20179/8/2017
5/1/2017quarterly$0.522.55%5/11/20175/15/20176/9/2017
12/13/2016quarterly$0.523.03%2/13/20172/15/20173/10/2017
10/17/2016quarterly$0.512.59%11/10/201611/15/201612/9/2016
6/20/2016quarterly$0.512.81%8/11/20168/15/20169/9/2016
5/2/2016quarterly$0.512.68%5/11/20165/13/20166/10/2016
12/8/2015quarterly$0.512.43%2/10/20162/12/20163/10/2016
10/19/2015quarterly$0.502.57%11/10/201511/13/201512/10/2015
6/15/2015quarterly$0.502.42%8/12/20158/14/20159/10/2015
5/4/2015quarterly$0.502.78%5/14/20155/18/20156/10/2015
12/15/2014quarterly$0.502.89%2/11/20152/13/20153/10/2015
10/20/2014quarterly$0.493.03%11/12/201411/14/201412/10/2014
6/16/2014quarterly$0.493.31%8/13/20148/15/20149/10/2014
5/5/2014quarterly$0.493.35%5/13/20145/15/20146/10/2014
12/16/2013quarterly$0.493.98%2/12/20142/14/20143/10/2014
10/21/2013quarterly$0.493.91%11/13/201311/15/201312/10/2013
6/18/2013quarterly$0.493.82%8/13/20138/15/20139/10/2013
5/6/2013quarterly$0.493.62%5/14/20135/16/20136/10/2013
12/17/2012quarterly$0.493.96%2/13/20132/15/20133/8/2013
(Data available from 1/1/2013 forward)

Insider Trades

Eli Lilly and (NYSE LLY) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.20%
Institutional Ownership Percentage: 76.43%
Insider Trades by Quarter for Eli Lilly and (NYSE:LLY)
Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Eli Lilly and (NYSE LLY) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/4/2017Susan MahonySVPSell36,585$86.18$3,152,895.30View SEC Filing  
11/10/2017Alfonso G ZuluetaSVPSell2,003$83.67$167,591.01View SEC Filing  
10/4/2017Lilly Endowment IncMajor ShareholderSell205,000$86.81$17,796,050.00View SEC Filing  
9/29/2017Lilly Endowment IncMajor ShareholderSell195,000$85.14$16,602,300.00View SEC Filing  
9/15/2017Lilly Endowment IncMajor ShareholderSell190,000$82.53$15,680,700.00View SEC Filing  
8/31/2017Lilly Endowment IncMajor ShareholderSell180,000$81.06$14,590,800.00View SEC Filing  
7/31/2017Lilly Endowment IncMajor ShareholderSell220,000$83.09$18,279,800.00View SEC Filing  
6/22/2017Lilly Endowment IncMajor ShareholderSell210,000$84.43$17,730,300.00View SEC Filing  
6/20/2017Lilly Endowment IncMajor ShareholderSell215,000$83.05$17,855,750.00View SEC Filing  
6/12/2017Melissa S BarnesInsiderSell1,900$80.78$153,482.00View SEC Filing  
6/9/2017Michael J HarringtonVPSell22,833$79.97$1,825,955.01View SEC Filing  
5/4/2017Enrique A ConternoSVPSell25,000$82.76$2,069,000.00View SEC Filing  
3/30/2017Lilly Endowment IncMajor ShareholderSell210,000$84.67$17,780,700.00View SEC Filing  
2/17/2017Lilly Endowment IncMajor ShareholderSell230,000$80.27$18,462,100.00View SEC Filing  
2/6/2017Alfonso G ZuluetaSVPSell15,000$77.66$1,164,900.00View SEC Filing  
2/3/2017Derica W RiceEVPSell11,162$77.14$861,036.68View SEC Filing  
2/2/2017Donald A ZakrowskiInsiderSell2,000$77.52$155,040.00View SEC Filing  
2/1/2017Lilly Endowment IncMajor ShareholderSell220,000$77.35$17,017,000.00View SEC Filing  
12/16/2016Lilly Endowment IncMajor ShareholderSell200,000$72.59$14,518,000.00View SEC Filing  
12/16/2016Melissa S BarnesInsiderSell2,093$82.23$172,107.39View SEC Filing  
12/16/2016R David HooverDirectorBuy500$71.85$35,925.00View SEC Filing  
12/16/2016Susan MahonySVPSell20,242$72.65$1,470,581.30View SEC Filing  
10/5/2016Maria A CroweInsiderSell2,248$81.37$182,919.76View SEC Filing  
8/15/2016Jackson P TaiDirectorBuy5,773$80.43$464,322.39View SEC Filing  
8/12/2016Jackson P TaiDirectorBuy2,560$80.42$205,875.20View SEC Filing  
7/29/2016Lilly Endowment IncMajor ShareholderSell205,000$82.94$17,002,700.00View SEC Filing  
7/28/2016Donald A ZakrowskiInsiderSell1,213$83.16$100,873.08View SEC Filing  
7/28/2016Lilly Endowment IncMajor ShareholderSell240,000$82.87$19,888,800.00View SEC Filing  
7/12/2016Lilly Endowment IncMajor ShareholderSell210,000$79.54$16,703,400.00View SEC Filing  
7/7/2016Lilly Endowment IncMajor ShareholderSell225,000$79.14$17,806,500.00View SEC Filing  
6/30/2016Lilly Endowment IncMajor ShareholderSell215,000$78.46$16,868,900.00View SEC Filing  
6/29/2016Lilly Endowment IncMajor ShareholderSell220,000$77.86$17,129,200.00View SEC Filing  
6/10/2016Melissa S BarnesSVPSell992$73.77$73,179.84View SEC Filing  
5/31/2016Lilly Endowment IncMajor ShareholderSell200,000$75.12$15,024,000.00View SEC Filing  
5/12/2016Jackson P TaiDirectorBuy1,080$75.75$81,810.00View SEC Filing  
5/12/2016Lilly Endowment IncMajor ShareholderSell190,000$75.86$14,413,400.00View SEC Filing  
5/2/2016Donald A ZakrowskiCAOSell1,600$75.86$121,376.00View SEC Filing  
4/29/2016Lilly Endowment IncMajor ShareholderSell180,000$75.44$13,579,200.00View SEC Filing  
4/27/2016Alfonso G ZuluetaSVPSell12,000$76.27$915,240.00View SEC Filing  
4/8/2016Lilly Endowment IncMajor ShareholderSell200,000$74.29$14,858,000.00View SEC Filing  
2/5/2016Stephen F FrySVPSell15,230$78.87$1,201,190.10View SEC Filing  
2/3/2016David A. RicksSVPSell5,733$77.66$445,224.78View SEC Filing  
2/3/2016Derica W. RiceCFOSell10,483$77.78$815,367.74View SEC Filing  
2/1/2016Jackson P TaiDirectorBuy3,170$78.62$249,225.40View SEC Filing  
1/29/2016Alfonso G ZuluetaSVPSell5,000$78.75$393,750.00View SEC Filing  
12/21/2015Lilly Endowment IncMajor ShareholderSell205,000$86.00$17,630,000.00View SEC Filing  
12/15/2015Lilly Endowment IncMajor ShareholderSell215,000$85.60$18,404,000.00View SEC Filing  
12/9/2015Enrique A ConternoVPSell25,000$83.88$2,097,000.00View SEC Filing  
12/2/2015Lilly Endowment Incmajor shareholderSell210,000$85.09$17,868,900.00View SEC Filing  
11/20/2015Lilly Endowment Incmajor shareholderSell205,000$84.54$17,330,700.00View SEC Filing  
10/29/2015Lilly Endowment Incmajor shareholderSell200,000$82.28$16,456,000.00View SEC Filing  
10/9/2015Lilly Endowment Incmajor shareholderSell215,000$85.86$18,459,900.00View SEC Filing  
10/5/2015Lilly Endowment Incmajor shareholderSell260,000$86.46$22,479,600.00View SEC Filing  
9/18/2015Lilly Endowment Incmajor shareholderSell250,000$89.04$22,260,000.00View SEC Filing  
6/10/2015Lilly Endowment IncMajor ShareholderSell210,000$82.39$17,301,900.00View SEC Filing  
6/4/2015Lilly Endowment IncMajor ShareholderSell200,000$77.90$15,580,000.00View SEC Filing  
5/29/2015Jeffrey N SimmonsSVPSell20,000$78.08$1,561,600.00View SEC Filing  
5/20/2015Lilly Endowment IncMajor ShareholderSell190,000$73.43$13,951,700.00View SEC Filing  
5/15/2015Lilly Endowment IncMajor ShareholderSell200,000$72.83$14,566,000.00View SEC Filing  
5/8/2015Lilly Endowment IncMajor ShareholderSell195,000$73.28$14,289,600.00View SEC Filing  
5/1/2015Lilly Endowment IncMajor ShareholderSell200,000$73.09$14,618,000.00View SEC Filing  
3/30/2015Lilly Endowment IncMajor ShareholderSell180,000$73.94$13,309,200.00View SEC Filing  
3/23/2015Lilly Endowment IncMajor ShareholderSell190,000$76.97$14,624,300.00View SEC Filing  
3/9/2015Stephen F FrySVPSell4,000$69.27$277,080.00View SEC Filing  
2/4/2015David A RicksSVPSell3,147$69.99$220,258.53View SEC Filing  
2/4/2015Derica W RiceCFOSell5,316$70.00$372,120.00View SEC Filing  
2/4/2015Jan M LundbergEVPSell11,085$70.08$776,836.80View SEC Filing  
2/3/2015Jan M LundbergEVPSell121,711$70.78$8,614,704.58View SEC Filing  
2/2/2015David A RicksSVPSell4,769$71.51$341,031.19View SEC Filing  
2/2/2015Derica W RiceCFOSell10,068$71.84$723,285.12View SEC Filing  
12/4/2014Lilly Endowment IncMajor ShareholderSell190,000$71.92$13,664,800.00View SEC Filing  
12/2/2014Lilly Endowment IncMajor ShareholderSell180,000$70.14$12,625,200.00View SEC Filing  
11/13/2014Lilly Endowment IncMajor ShareholderSell200,000$67.73$13,546,000.00View SEC Filing  
11/5/2014Lilly Endowment IncMajor ShareholderSell180,000$67.00$12,060,000.00View SEC Filing  
11/4/2014Fionnuala M WalshSVPSell15,000$67.00$1,005,000.00View SEC Filing  
11/3/2014Enrique A ConternoVPSell5,000$66.03$330,150.00View SEC Filing  
10/31/2014Fionnuala M WalshSVPSell7,376$66.58$491,094.08View SEC Filing  
10/31/2014Lilly Endowment IncMajor ShareholderSell190,000$66.40$12,616,000.00View SEC Filing  
10/30/2014Lilly Endowment IncMajor ShareholderSell175,000$66.58$11,651,500.00View SEC Filing  
10/24/2014Maria A CroweInsiderSell2,750$65.77$180,867.50View SEC Filing  
10/6/2014Lilly Endowment IncMajor ShareholderSell210,000$65.63$13,782,300.00View SEC Filing  
10/1/2014Enrique A ConternoVPSell5,000$64.86$324,300.00View SEC Filing  
9/30/2014Lilly Endowment IncMajor ShareholderSell200,000$65.07$13,014,000.00View SEC Filing  
9/10/2014Lilly Endowment IncMajor ShareholderSell210,000$64.77$13,601,700.00View SEC Filing  
9/3/2014Lilly Endowment IncMajor ShareholderSell200,000$63.99$12,798,000.00View SEC Filing  
9/2/2014Enrique A ConternoVPSell5,000$63.60$318,000.00View SEC Filing  
7/29/2014Lilly Endowment IncMajor ShareholderSell250,000$63.03$15,757,500.00View SEC Filing  
7/28/2014Susan MahonySVPSell2,065$63.30$130,714.50View SEC Filing  
7/25/2014Enrique A ConternoVPSell10,000$63.79$637,900.00View SEC Filing  
7/25/2014Susan MahonySVPSell30,000$63.90$1,917,000.00View SEC Filing  
7/1/2014Lilly Endowment IncMajor ShareholderSell235,000$62.30$14,640,500.00View SEC Filing  
6/25/2014Lilly Endowment IncMajor ShareholderSell245,000$62.68$15,356,600.00View SEC Filing  
6/20/2014Lilly Endowment IncMajor ShareholderSell230,000$61.55$14,156,500.00View SEC Filing  
6/16/2014Lilly Endowment IncMajor ShareholderSell200,000$58.73$11,746,000.00View SEC Filing  
6/5/2014Lilly Endowment IncMajor ShareholderSell190,000$59.53$11,310,700.00View SEC Filing  
5/21/2014Lilly Endowment Incmajor shareholderSell230,000$58.90$13,547,000.00View SEC Filing  
5/12/2014Jackson TaiDirectorBuy17,157$59.19$1,015,522.83View SEC Filing  
5/12/2014Lilly Endowment Incmajor shareholderSell210,000$59.33$12,459,300.00View SEC Filing  
5/6/2014Lilly Endowment Incmajor shareholderSell190,000$58.79$11,170,100.00View SEC Filing  
4/29/2014Lilly Endowment Incmajor shareholderSell200,000$59.43$11,886,000.00View SEC Filing  
4/28/2014Lilly Endowment Incmajor shareholderSell150,000$58.64$8,796,000.00View SEC Filing  
8/15/2013Enrique ConternoVPSell5,000$53.79$268,950.00View SEC Filing  
7/29/2013Jacques TapieroSVPSell7,500$53.74$403,050.00View SEC Filing  
7/15/2013Enrique A ConternoVPSell5,000$51.43$257,150.00View SEC Filing  
6/17/2013Enrique A ConternoVPSell5,000$52.45$262,250.00View SEC Filing  
5/15/2013Enrique A ConternoVPSell5,000$56.15$280,750.00View SEC Filing  
5/10/2013Jeffrey N SimmonsSVPSell10,000$54.49$544,900.00View SEC Filing  
3/26/2013Susan MahonySVPSell5,000$56.00$280,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Eli Lilly and (NYSE LLY) News Headlines

Source:
DateHeadline
Lilly Reports Top-Line Results from CYRAMZA® (ramucirumab) Phase 3 Study in First-Line Advanced Gastric CancerLilly Reports Top-Line Results from CYRAMZA® (ramucirumab) Phase 3 Study in First-Line Advanced Gastric Cancer
finance.yahoo.com - December 9 at 9:59 AM
Lillys stomach cancer drug meets main goal, but fails to improve survival rateLilly's stomach cancer drug meets main goal, but fails to improve survival rate
finance.yahoo.com - December 9 at 9:59 AM
See what the IHS Markit Score report has to say about Eli Lilly And Co.See what the IHS Markit Score report has to say about Eli Lilly And Co.
finance.yahoo.com - December 8 at 4:50 PM
How Is Eli Lilly’s Taltz Positioned Now?How Is Eli Lilly’s Taltz Positioned Now?
finance.yahoo.com - December 8 at 4:50 PM
How Eli Lilly’s Forteo and Jardiance Are PerformingHow Eli Lilly’s Forteo and Jardiance Are Performing
finance.yahoo.com - December 8 at 9:58 AM
How Eli Lilly’s Endocrinology Drugs Are PerformingHow Eli Lilly’s Endocrinology Drugs Are Performing
finance.yahoo.com - December 8 at 9:58 AM
How Eli Lilly’s Trajenta, Trulicity, and Basaglar Are PerformingHow Eli Lilly’s Trajenta, Trulicity, and Basaglar Are Performing
finance.yahoo.com - December 8 at 9:58 AM
How Eli Lilly’s Cardiovascular Portfolio PerformedHow Eli Lilly’s Cardiovascular Portfolio Performed
finance.yahoo.com - December 7 at 5:14 PM
How Did Eli Lilly Perform in 3Q17?How Did Eli Lilly Perform in 3Q17?
finance.yahoo.com - December 7 at 5:14 PM
Juno Therapeutics (JUNO) Reports Licensing Agreements with Lilly (LLY), OncoTracker, and Fred Hutchinson Cancer Research CenterJuno Therapeutics (JUNO) Reports Licensing Agreements with Lilly (LLY), OncoTracker, and Fred Hutchinson Cancer Research Center
www.streetinsider.com - December 7 at 10:16 AM
With -8.7% Earnings Drop Lately, Did Eli Lilly and Company (LLY) Underperform Its Industry?With -8.7% Earnings Drop Lately, Did Eli Lilly and Company (LLY) Underperform Its Industry?
finance.yahoo.com - December 7 at 10:16 AM
Eli Lilly & Co. (LLY) Initiates Clinical Trial to Evaluate Functionality, Safety of its Automated Insulin Delivery ... - StreetInsider.comEli Lilly & Co. (LLY) Initiates Clinical Trial to Evaluate Functionality, Safety of its Automated Insulin Delivery ... - StreetInsider.com
www.streetinsider.com - December 6 at 4:57 PM
Viagra goes generic: Pfizer to launch own little white pillViagra goes generic: Pfizer to launch own little white pill
marketbeat.com - December 6 at 12:23 PM
Juno Therapeutics Signs Licensing Agreements with Lilly, OncoTracker, and Fred Hutchinson Cancer Research Center to Advance Its BCMA-Directed Engineered T Cell Program in ...Juno Therapeutics Signs Licensing Agreements with Lilly, OncoTracker, and Fred Hutchinson Cancer Research Center to Advance Its BCMA-Directed Engineered T Cell Program in ...
www.businesswire.com - December 6 at 10:08 AM
Eli Lilly and Company (LLY) SVP Sells $3,152,895.30 in StockEli Lilly and Company (LLY) SVP Sells $3,152,895.30 in Stock
www.americanbankingnews.com - December 5 at 8:34 PM
Eli Lilly and (LLY) Given a $73.00 Price Target by BMO Capital Markets AnalystsEli Lilly and (LLY) Given a $73.00 Price Target by BMO Capital Markets Analysts
www.americanbankingnews.com - December 5 at 6:34 PM
FDA approves diabetes drug that also helps with weight lossFDA approves diabetes drug that also helps with weight loss
finance.yahoo.com - December 5 at 4:52 PM
Eli Lilly & Co. (LLY) Initiates Clinical Trial to Evaluate Functionality, Safety of its Automated Insulin Delivery SystemEli Lilly & Co. (LLY) Initiates Clinical Trial to Evaluate Functionality, Safety of its Automated Insulin Delivery System
www.streetinsider.com - December 5 at 10:41 AM
Blog Exposure - FDA Approves Eli Lillys Taltz(R) for the Treatment of Active PsABlog Exposure - FDA Approves Eli Lilly's Taltz(R) for the Treatment of Active PsA
finance.yahoo.com - December 5 at 10:41 AM
Lilly Initiates Clinical Trial to Evaluate the Functionality and Safety of its Automated Insulin Delivery SystemLilly Initiates Clinical Trial to Evaluate the Functionality and Safety of its Automated Insulin Delivery System
finance.yahoo.com - December 5 at 10:41 AM
Eli Lillys Taltz Now Approved for Psoriatic Arthritis, Bringing Key Competition for Rival IL-17 Inhibitor, Novartis CosentyxEli Lilly's Taltz Now Approved for Psoriatic Arthritis, Bringing Key Competition for Rival IL-17 Inhibitor, Novartis' Cosentyx
www.bizjournals.com - December 4 at 4:54 PM
Eli Lilly on the Street: Analyst Recommendations in NovemberEli Lilly on the Street: Analyst Recommendations in November
finance.yahoo.com - December 4 at 9:58 AM
Lilly's (LLY) Taltz Gets Approval for Label Expansion in USLilly's (LLY) Taltz Gets Approval for Label Expansion in US
finance.yahoo.com - December 4 at 9:58 AM
Eli Lilly’s (LLY) Upgraded to BuyEli Lilly’s (LLY) Upgraded to Buy
investorplace.com - December 1 at 5:16 PM
Lillys Taltz® (ixekizumab) Receives U.S. FDA Approval for the Treatment of Active Psoriatic ArthritisLilly's Taltz® (ixekizumab) Receives U.S. FDA Approval for the Treatment of Active Psoriatic Arthritis
finance.yahoo.com - December 1 at 5:16 PM
Understanding Eli Lilly’s Estimates after 3Q17Understanding Eli Lilly’s Estimates after 3Q17
finance.yahoo.com - December 1 at 5:16 PM
Understanding Eli Lilly’s Valuation This NovemberUnderstanding Eli Lilly’s Valuation This November
finance.yahoo.com - December 1 at 5:16 PM
Eli Lilly’s (LLY) Upgraded to BuyEli Lilly’s (LLY) Upgraded to Buy
investorplace.com - December 1 at 11:45 AM
Inside Eli Lilly’s Animal Health Business in 3Q17Inside Eli Lilly’s Animal Health Business in 3Q17
finance.yahoo.com - November 30 at 4:53 PM
Behind Eli Lilly’s Cymbalta and Other Neuroscience Products in 3Q17Behind Eli Lilly’s Cymbalta and Other Neuroscience Products in 3Q17
finance.yahoo.com - November 30 at 10:27 AM
Eli Lilly’s Cialis and Other Cardiovascular Products in 3Q17Eli Lilly’s Cialis and Other Cardiovascular Products in 3Q17
finance.yahoo.com - November 30 at 10:27 AM
Eli Lilly and Company (LLY) Expected to Post Quarterly Sales of $5.93 BillionEli Lilly and Company (LLY) Expected to Post Quarterly Sales of $5.93 Billion
www.americanbankingnews.com - November 30 at 4:08 AM
New, long-acting drugs cut frequency of migraine headachesNew, long-acting drugs cut frequency of migraine headaches
marketbeat.com - November 29 at 5:28 PM
The Case for Eli Lilly and Co. - Motley FoolThe Case for Eli Lilly and Co. - Motley Fool
www.fool.com - November 29 at 5:15 PM
Senators of both parties quiz Trump health pick on drug costSenators of both parties quiz Trump health pick on drug cost
finance.yahoo.com - November 29 at 5:15 PM
Behind Eli Lilly’s Alimta and Other Oncology Products in 3Q17Behind Eli Lilly’s Alimta and Other Oncology Products in 3Q17
finance.yahoo.com - November 29 at 5:15 PM
[$$] HHS Nominee Says He Has Prescription to Lower Drug Costs[$$] HHS Nominee Says He Has Prescription to Lower Drug Costs
finance.yahoo.com - November 29 at 5:15 PM
How Eli Lilly’s Business Segments Performed in 3Q17How Eli Lilly’s Business Segments Performed in 3Q17
finance.yahoo.com - November 29 at 10:04 AM
Behind Eli Lilly’s Humalog and Other Endocrine Products in 3Q17Behind Eli Lilly’s Humalog and Other Endocrine Products in 3Q17
finance.yahoo.com - November 29 at 10:04 AM
Eli Lilly’s New Pharmaceutical Products in 3Q17Eli Lilly’s New Pharmaceutical Products in 3Q17
finance.yahoo.com - November 29 at 10:04 AM
Skeptical Democrats to quiz Trump health pick on drug pricesSkeptical Democrats to quiz Trump health pick on drug prices
marketbeat.com - November 29 at 3:46 AM
Zacks: Brokerages Anticipate Eli Lilly and Company (LLY) to Announce $1.07 EPSZacks: Brokerages Anticipate Eli Lilly and Company (LLY) to Announce $1.07 EPS
www.americanbankingnews.com - November 28 at 9:10 PM
Inside Eli Lilly’s Revenue Trends in 3Q17Inside Eli Lilly’s Revenue Trends in 3Q17
finance.yahoo.com - November 28 at 4:52 PM
Analyst Recommendations for Nektar Therapeutics in November 2017Analyst Recommendations for Nektar Therapeutics in November 2017
finance.yahoo.com - November 28 at 4:52 PM
In Trump health secretary pick, Dems have questions but hopeIn Trump health secretary pick, Dems have questions but hope
marketbeat.com - November 28 at 1:35 PM
Learn From My Portfolio Mistakes: Cramers Mad Money Recap (Monday 11/27/17)Learn From My Portfolio Mistakes: Cramer's 'Mad Money' Recap (Monday 11/27/17)
finance.yahoo.com - November 28 at 10:00 AM
World Cyclin-Dependent Kinase (CDK) Inhibitors Therapeutics Pipeline Analysis 2017 - Key Players are Eli Lilly and Company, Merck & Co. & AstraZeneca - Research and MarketsWorld Cyclin-Dependent Kinase (CDK) Inhibitors Therapeutics Pipeline Analysis 2017 - Key Players are Eli Lilly and Company, Merck & Co. & AstraZeneca - Research and Markets
www.businesswire.com - November 27 at 5:05 PM
ETFs with exposure to Eli Lilly & Co. : November 27, 2017ETFs with exposure to Eli Lilly & Co. : November 27, 2017
finance.yahoo.com - November 27 at 5:05 PM
He Raised Drug Prices at Eli Lilly. Can He Lower Them for the U.S.?He Raised Drug Prices at Eli Lilly. Can He Lower Them for the U.S.?
www.nytimes.com - November 26 at 5:05 PM
Analytics for Quant Score Drive Upgrade of Eli Lilly (LLY) to Buy - Investorplace.comAnalytics for Quant Score Drive Upgrade of Eli Lilly (LLY) to Buy - Investorplace.com
investorplace.com - November 25 at 9:42 AM

SEC Filings

Eli Lilly and (NYSE:LLY) SEC Filings

DateFilerForm TypeView
12/05/2017
4:48 PM
Eli Lilly and (Issuer)
Zakrowski Donald A (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
View Filing
12/05/2017
4:46 PM
Fry Stephen F (Reporting)
Eli Lilly and (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
View Filing
12/05/2017
4:43 PM
Eli Lilly and (Issuer)
Ricks David A (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
View Filing
12/05/2017
4:35 PM
Eli Lilly and (Issuer)
Zulueta Alfonso G (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
View Filing
12/05/2017
4:32 PM
Eli Lilly and (Issuer)
Mahony Susan (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
View Filing

Social Media

Financials

Eli Lilly and (NYSE:LLY) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Eli Lilly and (NYSE LLY) Stock Chart for Monday, December, 11, 2017

Loading chart…

This page was last updated on 12/11/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.